Vasculogenic mimicry in non-small cell lung cancer: a systematic review
- PMID: 40786517
- PMCID: PMC12331492
- DOI: 10.3389/fonc.2025.1481726
Vasculogenic mimicry in non-small cell lung cancer: a systematic review
Abstract
Vasculogenic mimicry (VM), a non-endothelial tumor blood supply mechanism linked to poor prognosis in various cancers, requires consolidated prognostic evaluation in non-small cell lung cancer (NSCLC). This systematic review synthesized evidence on VM's association with survival outcomes (OS, DFS, PFS) in NSCLC patients. Following PRISMA-ScR guidelines, PubMed and Google Scholar were searched, identifying 19 eligible studies (all in Chinese populations) using immunohistochemistry (CD31/CD34-PAS) for VM detection. Eighteen studies found VM presence (prevalence 13.6%-45.2%) significantly associated with worse survival. Multivariate analyses identified VM as an independent negative prognostic factor, increasing mortality risk (HR 1.542-2.542) and progression risk (HR 2.1-2.4). However, critical limitations included exclusive focus on Asian cohorts, universal retrospective design, inconsistencies and potential artifacts in VM detection, and statistical issues (misreported risk measures, discordant data). While VM correlates with reduced survival in NSCLC, suggesting potential prognostic utility, these limitations - particularly ethnic homogeneity, retrospective bias, methodological heterogeneity, and statistical errors - preclude definitive conclusions. Future prospective studies with standardized VM assessment and diverse populations are essential for validation.
Keywords: histology; non-small cell lung cancer; prognosis; systematic review; vasculogenic mimicry.
Copyright © 2025 Shapkina, Shindyapin, Burlov, Prosekina and Artemyeva.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer.J Cancer Res Clin Oncol. 2023 Sep;149(11):8729-8741. doi: 10.1007/s00432-023-04790-3. Epub 2023 May 2. J Cancer Res Clin Oncol. 2023. PMID: 37129607 Free PMC article.
-
Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis.Eur J Cancer. 2013 Dec;49(18):3914-23. doi: 10.1016/j.ejca.2013.07.148. Epub 2013 Aug 27. Eur J Cancer. 2013. PMID: 23992642
-
Potential for tumor aggressiveness and its association with vasculogenic mimicry marker in colorectal carcinomas in Indian population- A tertiary care hospital level study.Indian J Pathol Microbiol. 2025 Apr 1;68(2):261-266. doi: 10.4103/ijpm.ijpm_792_23. Epub 2024 Sep 2. Indian J Pathol Microbiol. 2025. PMID: 39221896
-
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Health Technol Assess. 2013. PMID: 23886301 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
References
-
- Prosekina EA, Shapkina VA, Karpov AE, Fedorutseva E, Artemyeva AS. The balance between deception and adaptation: vasculogenic mimicry as a tumor survival strategy. Usp. Mol onkol. (2025) 12:14–30. doi: 10.17650/2313-805X-2025-12-1-14-30 - DOI
Publication types
LinkOut - more resources
Full Text Sources